Ardea Biosciences — Corporate Update (May 2010)
35 slides from Ardea Biosciences's corporate update, May 10, 2010
Slide 1: Company Update
) Biosciences Designing Solutions for Serious Diseases Company Update May 10, 2010
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer 3 Gout RDEA594 Next Generation MEKI + sorafenib for cancer RDEA119 Gout RDEA119 3rd Gen NNRTIs
Slide 4: Gout/Hyperuricemia - Disease and URAT1 Mechanism
Gout/Hyperuricemia 4 - - Disease and URAT1 Mechanism
Slide 5: Dual-Energy CT Shows Extensive Deposition of Urate
Dual-Energy CT Shows Extensive Deposition of Urate Allopurinol, even with optimized dosing, produces very slow clearance of tophi (0.56 mm/month reduction in tophi with 29-month mean time to resolution)1 5 From Nicola Dalbeth 1. Perez-Ruiz F, Arthritis Rheum 2002;47:356-360
Slide 6: Hyperuricemia/Gout - Unmet Medical Need
Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Increasing incidence and severity in US: > 5,000,000 potential patients ~ 90% of patients are "under-excretors" of uric acid RDEA594 increases excretion back to normal levels Allopurinol an
Slide 7: Uric Acid Production and Elimination
Adapted from Hare, J. M. et al. Circulation 2003;107:1951-1953; Uric Acid Production and Elimination RDEA594 Probenecid Benzbromarone* 7 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. 1. Perez-Ruiz F, Arthritis Rheum 2002;47:356-360 Peglotic
Slide 8: RDEA594 Normalizes Uric Acid Excretion
RDEA594 Normalizes Uric Acid Excretion Gout patients RDEA594 normalizes uric acid excretion in gout patients with inadequate excretion Allopurinol reduces uric acid excretion even further in patients with already low excretion The combination of these two agents reduces production, but also increase
Slide 9: RDEA594 URAT1 Inhibitor Mechanism for Under-excretors
Diet & Metabolism <400 mg/day Diet & Metabolism 600-800 mg/day Joint Tophus 10 mg/dL 6 mg/dL serum level Xanthine Oxidase Inhibitor RDEA594 - URAT1 Inhibitor <5 mg/dL RDEA594 is most appropriate mechanism for under- excretors and is additive to allopurinol and febuxostat urine urine 200 mg/day 9 600
Slide 10: Benzbromarone demonstrates benefit of combining URAT1 and xanthine oxidase inhibitors
10 Benzbromarone demonstrates benefit of combining URAT1 and xanthane oxidase inhibitors Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone (not approved in U.S.; limited approvals in E.U.; sold in Japan with "Black-box" type warning) is a URAT1 inhibitor Over 10 m
Slide 11: Gout/Hyperuricemia - Market Dynamics and Opportunity
Gout/Hyperuricemia 11 - - Market Dynamics and Opportunity
Slide 12: US Gout Patient Distribution
US Gout Patient Distribution 12 Diagnosed Gout 5.2M ~50% ~90% ~50% ~50% Allopurinol Treated 2.5M Responders (<6mg/dL) 1.25M Severe Chronic Gout 0.1 - 0.3M (3) Allopurinol Non-Responders 1.25M ~10-20% Small % Allopurinol Intollerant Gout Pts on ULT 2.6M Small % Education (DTC) Improved Compliance
Slide 13: Very Low Drug Adherence Rate for Urate Lowering Therapies
Very Low Drug Adherence Rate for Urate Lowering Therapies Lowering Therapies Lowering Therapies 13 Source: Briesacher et al.; Pharmacotherpy 2008 If patients took their gout meds at the same rate as their hypertension meds, there would be almost twice as many scripts for gout meds
Slide 14: Competitive Landscape - Xanthine Oxidase Inhibitors: Allopurinol
Competitive Landscape - Xanthine Oxidase Inhibitors Allopurinol 40-year old generic xanthine oxidase inhibitor: 36-42% response rate in three large Phase 3 trials (mean ~33% reduction in sUA) 8% SAEs1 and 0.4% incidence of Allopurinol Hypersensitivity Syndrome (AHS), which is 20-25% fatal2 Note: com
Slide 15: Competitive Landscape - Xanthine Oxidase Inhibitors: Febuxostat
Competitive Landscape - Xanthine Oxidase Inhibitors Febuxostat (Takeda) Another xanthine oxidase inhibitor approved 2-09 in US; not significantly differentiated from allopurinol The 40 mg starting dose is equivalent to allopurinol; 80 mg has improved efficacy Safety profile similar to allopurinol Ap
Slide 16: Competitive Landscape - Adverse Events With Xanthine Oxidase Inhibitors
Competitive Landscape - No Difference in Most Common Adverse Events With Xanthine Oxidase Inhibitors Adverse Event Placebo Febuxostat 40 mg 80 mg Febuxostat 40 mg 80 mg Allopurinol N= 134 757 1279 1277 Liver Function Abnormalities 0.7% 6.6% 4.6% 4.2% Nausea 0.7% 1.1% 1.3% 0.8% Arthralgia 0% 1.1% 0.7
Slide 17: Competitive Landscape - Uricosuric Inhibitor of Multiple Renal Transporters
Competitive Landscape - Uricosuric Inhibitor of Multiple Renal Transporters Probenecid (Benuryl) Suboptimal dosing frequency: 500 mg BID to 500 mg QID Low to modest efficacy: 23% reduction in sUA with 1 gm/day and 31% reduction with 2 gm/day 1 Side Effects: Headache, anorexia, nausea, vomiting, diar
Slide 18: Two timeframes for flares
Two timeframes for flares Two timeframes for flares 18 Colchicine Prophylaxis Febuxostat FACT study Sharp rise in flares after two months of colchicine was stopped Improvement in flares with more potent therapy not seen until after week 44 Note: Approx. same flare rate with allopurinol at 1 month an
Slide 19: Almost Half of Patients Under Treatment are Still Having Flares
Almost Half of Patients Under Treatment are Still Having Flares - Lower sUA Reduces Flares Having Flares - Lower sUA Reduces Flares Having Flares - Lower sUA Reduces Flares 19 Proportion of Subjects (%) Abstract 758: MA Becker, et al. ACR Boston November 2007 *Ardea Market Research Only 2% of patien
Slide 20: RDEA594 Opportunity to Reduce Flares
RDEA594 Opportunity to Reduce Flares Chronic therapy: The combination of RDEA594 (URAT1 inhibitor) and xanthine oxidase inhibitors will produce greater reductions in sUA than either mechanism alone, with many more patients reaching levels below 6 mg/dL, and even below 5 mg/dL Reduction of sUA from 6
Slide 21: Gout and Hyperuricemia - Three Key Opportunities
Gout and Hyperuricemia - Three Key Opportunities Combination Therapy - Potential to Redefine the Standard of Care Approximately 1/2 of treated patients still having flares; consistent with 40% response rate to allopurinol Adding RDEA594 could significantly reduce sUA and the incidence of gout flares
Slide 22: Gout/Hyperuricemia - Clinical Development
Gout/Hyperuricemia 22 - - Clinical Development
Slide 23: RDEA594 - Clinical Summary
23 RDEA594 - Clinical Summary Phase 2a combination with allopurinol - completed Combination reduced serum uric acid greater than either agent alone POC combination with febuxostat - completed Combination reduced serum acid greater than either agent alone Combination achieved >70% reduction of serum
Slide 24: Phase 2a: 83% Response in Renally Impaired Patients
Phase 2a: 83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Sub
Slide 25: Phase 2a: RDEA594 and allopurinol combination reduced sUA
Phase 2a: RDEA594 and allopurinol combination reduced sUA greater than either drug alone N=5 N=5 N=5 Cohorts 1&2 combined Data excludes overproducers; trough samples out to Day 21. LOCF used for allopurinol due to incomplete data N=10 RDEA594 400 mg + Allopurinol produced a reduction of sUA from a m
Slide 26: RDEA594 Febuxostat Drug-Drug Interaction and PD Study
RDEA594 -105: Phase 1 Placebo-Controlled RDEA594 - - Febuxostat Drug-Drug Interaction and PD Study Population: 36 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive 2 panels with escalating doses of RDEA594 or placebo
Slide 27: Combination of RDEA594 and Febuxostat Produced 70%-80% Reductions in sUA
Combination of RDEA594 and Febuxostat Produced 70% - 80% Reductions in sUA Mean percent sUA reduction observed with pegloticase* * *Khosravan, et al. Clin Pharmacokinet 2006; 45 (8): 821-841 27 The combination arms are significantly different from febuxostat alone at all points from Days 9-15: p < 0
Slide 28: Overall Summary of Safety for RDEA594 Through Phase 2a
Overall Summary of Safety for RDEA594 Through Phase 2a Patients exposed to RDEA594 (either administration of RDEA594 or RDEA806): Healthy subjects and HIV pts ~360 for up to 14 days Gout patients ~ 40 for up to 28 days Control subjects ~ 88 28 Arm Discontinuations Due to AEs N (%) Serious Adverse Ev
Slide 29: RDEA594 Phase 2b Monotherapy Study - Design
RDEA594 Phase 2b Monotherapy Study - Design 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 123 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose was titrated up weekly Endpoints: Proportio
Slide 30: RDEA594 Phase 2b Monotherapy Study Top-Line Results
RDEA594 Phase 2b Monotherapy Study Full Data to be Presented at 2010 EULAR Preliminary, Top-Line Efficacy Results of Phase 2b Monotherapy Study of RDEA594 in the Treatment of Hyperuricemia in Gout Patients Preliminary, Top-Line Efficacy Results of Phase 2b Monotherapy Study of RDEA594 in the Treatme
Slide 31: Incidence of the Most Frequent Adverse Events
Incidence of the Most Frequent Adverse Events* 31 *Adverse events reported by at least 2 subjects that were considered at least possibly related to treatment The was a 2% rate of transient elevations of serum creatinine during the screening period and during the drug treatment period Only two patien
Slide 32: RDEA594 Phase 2b Allopurinol Add-On Combination Study - Enrolling
RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Initial dose selection phase completed: RDEA594 200 mg, 400 mg, 600 mg to be evaluated 72 patients per dose level, including 48 patients randomized to RDEA594 and 24 patients randomized to placebo per cohort and tr
Slide 33: Cancer MEK program licensed to Bayer HealthCare
Cancer 33 MEK program licensed to Bayer HealthCare on April 28, 2009 $35 million upfront license fee Payments could total $407 million, excluding royalties Low double-digit royalties on worldwide sales Ardea responsible for completing two dose-finding studies (expected completion to MTD in 1H10)
Slide 34: Financial Position Summary
Financial Position Summary Statement of Operations (In thousands, except per share data) Three Months Ended March 31, 2010 Revenue Operating expenses Other expense $ 3,273 13,177 (179) NET LOSS $(10,083) NET LOSS PER SHARE $(0.54) In April 2010, we completed a public offering of 4,025,000 shares of
Slide 35: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Drug Candidate Event Date Date Gout Gout Gout Gout RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results Phase 2a - Cohort 2 Allopurinol Combo Results ? RDEA594 Febuxostat Combination Study Results Febuxostat Combination Study Results ? RDEA594 Phase 2b Monotherapy S